TWD 122.5
(-2.39%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 1.41 Billion TWD | 35.79% |
2022 | 1.04 Billion TWD | 165.15% |
2021 | 393.88 Million TWD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 1.65 Billion TWD | 16.38% |
2024 Q2 | 1.8 Billion TWD | 9.16% |
2023 Q4 | 1.41 Billion TWD | 58.85% |
2023 FY | 1.41 Billion TWD | 35.79% |
2023 Q1 | 980.52 Million TWD | -6.12% |
2023 Q2 | 919.88 Million TWD | -6.18% |
2023 Q3 | 892.78 Million TWD | -2.95% |
2022 Q4 | 1.04 Billion TWD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Apex Biotechnology Corp. | 2.29 Billion TWD | 38.261% |
Sinphar Pharmaceutical Co.,Ltd. | 6.25 Billion TWD | 77.313% |
Panion & Bf Biotech Inc. | 3.23 Billion TWD | 56.165% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 5.17 Billion TWD | 72.578% |
GenMont Biotech Incorporation | 1.65 Billion TWD | 14.217% |
Abnova (Taiwan) Corporation | 1.35 Billion TWD | -4.604% |
Adimmune Corporation | 9.48 Billion TWD | 85.048% |
Tanvex BioPharma, Inc. | 2.76 Billion TWD | 48.681% |
Polaris Group | 9.09 Billion TWD | 84.412% |
Energenesis Biomedical CO.,LTD. | 828.57 Million TWD | -71.157% |
UnicoCell Biomed Co., Ltd. | 685.92 Million TWD | -106.75% |